Equity grants to Gilead (GILD) director Jeffrey Bluestone detailed

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Gilead Sciences director Jeffrey Bluestone reported new equity awards. He received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, each representing one share of common stock, and the RSUs vested immediately on April 30, 2026. He was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with 100% of the option vesting immediately on the same date. Following these transactions, he holds 10,066 shares of Gilead common stock directly, in addition to the option position.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bluestone Jeffrey

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Option (Right to Buy)	4,884	$0.00	--
Grant/Award	Common Stock	1,146	$0.00	--

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 4,884 shares (Direct, null); Common Stock — 10,066 shares (Direct, null)

Footnotes (1)

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Key Figures

RSUs granted: 1,146 units Options granted: 4,884 shares Option exercise price: $130.84 per share +2 more

5 metrics

RSUs granted 1,146 units Restricted stock units granted April 30, 2026

Options granted 4,884 shares Non-qualified stock option grant April 30, 2026

Option exercise price $130.84 per share Non-qualified stock option strike price

Shares after transaction 10,066 shares Direct common stock holdings after awards

Option expiration April 30, 2036 Non-qualified stock option expiration date

Key Terms

restricted stock units ("RSUs"), Non-qualified Stock Option (Right to Buy), 2022 Equity Incentive Plan

3 terms

restricted stock units ("RSUs") financial

"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-qualified Stock Option (Right to Buy) financial

"Non-qualified Stock Option (Right to Buy) with an exercise price of $130.8400 per share."

2022 Equity Incentive Plan financial

"granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 04:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bluestone Jeffrey

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	04/30/2026		A		1,146	A	$0	10,066	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$130.84	04/30/2026		A		4,884		⁽²⁾	04/30/2036	Common Stock	4,884	$0	4,884	D

Explanation of Responses:

1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Remarks:

	/s/ Amy Kim by Power of Attorney for Jeffrey A. Bluestone	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Gilead Sciences (GILD) director Jeffrey Bluestone report on this Form 4?

Jeffrey Bluestone reported equity awards from Gilead Sciences, including restricted stock units and a non-qualified stock option. These awards increase his direct common stock holdings and give him additional rights to buy shares at a set exercise price.

How many restricted stock units did Jeffrey Bluestone receive from Gilead Sciences (GILD)?

He received 1,146 restricted stock units. Each RSU represents the contingent right to receive one share of Gilead Sciences common stock. According to the filing, all of these RSUs vested immediately on the grant date of April 30, 2026.

What stock options were granted to Jeffrey Bluestone by Gilead Sciences (GILD)?

He was granted a non-qualified stock option covering 4,884 shares of Gilead Sciences common stock. The option has an exercise price of $130.84 per share, and 100% of the shares subject to the option vested immediately on April 30, 2026.

How many Gilead Sciences (GILD) shares does Jeffrey Bluestone hold after these transactions?

Following the reported transactions, Jeffrey Bluestone directly holds 10,066 shares of Gilead Sciences common stock. This total reflects his position after the grant and immediate vesting of the 1,146 restricted stock units disclosed in the filing.

Did the restricted stock units granted to Jeffrey Bluestone in Gilead Sciences (GILD) vest immediately?

Yes. The 1,146 restricted stock units granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan vested immediately on April 30, 2026. Each vested RSU entitles him to receive one share of Gilead common stock, subject to the plan’s terms.

When do Jeffrey Bluestone’s Gilead Sciences (GILD) stock options expire?

The non-qualified stock option granted to Jeffrey Bluestone expires on April 30, 2036. Until that expiration date, he has the right to purchase up to 4,884 Gilead Sciences common shares at the fixed exercise price of $130.84 per share.